- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02991833
Developing Of A New Incontinence Care Product
"Developing Of A New Incontinence Care Product, And Investigation Of The Effect Of Its On Perineal Dermatitis in Woman Patients Fecal Incontinence"
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Urinary and faecal incontinence which affected the large number of people are common and embarrassing health problems. Urinary incontinence affects the life quality , and causes to isolation and depression. Faecal incontinence can cause to psychosocial problems such as loss of self-esteem, progressive isolation, social stigmatisation and reduces the life quality, also burden a high cost on the patients and the community . Both urinary and fecal incontinence may leads to incontinence-associated dermatitis (IAD), an inflamatory skin disease, which is a a clinical evolution of skin damage associated with moisture , as a result of chronic or repeated exposure of the skin to urine or fecal matter. In IAD shows as redness with or without blistering, erosion, or loss of the skin barrier function IAD which causes discomfort and stres for patients , is a serious and common problem in many health care setting and impacts patients' well-being. Health care professionals who are working in many health institutions struggled to giving the optimal care to keep incontinent patients' skin in a healthy condition. When IAD developed, the risk of infection, the length of hospitalization, and morbidity increases and those patients are at greater risk of developing a pressure ulser.
The research question was; are there differences in the incidence of IAD in patients with fecal incontinence by a new incontinece care versus adult diaper.
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
-
Izmir, Turkey
- Ege University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- bedridden patients who had fecal and urinary incontinence,
- had not diabetes mellitus,
- patients whose perineal and perianal skin is intact,
- had indwelling urethral catheter and
- patient who accepted to participate to the study
Exclusion Criteria:
- patients who had diabetes mellitus,
- patients whose had darkly pigmented area in the perineal and perianal area,
- patients had pressure ulcers or erithema
- who have not accepted to participate
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Of A New Incontinence Care Product
Patients were observed and evaluated daily during the morning care between 08:00 AM - 8:30 AM for a maximum 7 days.
The visual scale contrived by (Fader et al.(2003) which is based on International Contact Dermatit Score, was used for graded the severity of IAD.
Scoring is is 0-to 4 and when scoring is increased the severity of the IAD increased.
To evaluate skin integrity, the perineal skin of the patients was observed every day by researcher and was recorded to the Perineal Skin Integrity Assesment Form.
The number of defecation, stool consistency, and the number of care product ( the novel incontinent care product) was observed daily and was recorded to the Patient Observation Form.
The main study outcomes was IAD.
|
The novel incontinent care product is dressed and removed removed by opening both sides.
In the part surrounding the waist and thights of the novel incontinent care product flexibility is achieved by planting rubber bien.
When developing new incontinence care products was taken counselling from a faculty member from Department of Textile Engineering of one University Faculty of Engineering.
The insurance policies was prepared for each patients attended to the study (Number: 481360).New care product is put on the experimental group.
Perineal care was made to patients twice a day and after each defecation.
After each perineal care, the novel incontinent care product was changed.
|
|
Active Comparator: Diaper
Patients were observed and evaluated daily during the morning care between 08:00 AM - 8:30 AM for a maximum 7 days.
The visual scale contrived by (Fader et al.(2003) which is based on International Contact Dermatit Score, was used for graded the severity of IAD.
Scoring is is 0-to 4 and when scoring is increased the severity of the IAD increased.
To evaluate skin integrity, the perineal skin of the patients was observed every day by researcher and was recorded to the Perineal Skin Integrity Assesment Form.
The number of defecation, stool consistency, and the number of care product (diaper ) was observed daily and was recorded to the Patient Observation Form.
The main study outcomes was IAD.
|
In patients of the diaper group was used the optimum adult diaper (Pads, Linea TENA, SCA, Hygiene, Goteborg, Sweden) which was available in the market.
Perineal care was made to patients twice a day and after each defecation.
After each perineal care, the diaper was changed.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
A New Incontinence Care Product associated dermatitis
Time Frame: 3 months
|
Women patients were observed and evaluated daily during the morning care between 08:00 AM - 8:30 AM for a maximum 7 days.
The visual scale contrived by (Fader et al.(2003) which is based on International Contact Dermatit Score, was used for graded the severity of IAD.
Scoring is is 0-to 4 and when scoring is increased the severity of the IAD increased.
To evaluate skin integrity, the perineal skin of the patients was observed every day by researcher and was recorded to the Perineal Skin Integrity Assesment Form.
The number of defecation, stool consistency, and the number of care product (diaper and the novel incontinent care product) was observed daily and was recorded to the Patient Observation Form.
The main study outcomes was IAD.We defined IAD having an erithema score of 1 or more, in the skin of buttock, sacrum, thight and groin.
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diaper associated dermatitis
Time Frame: 3 months
|
Women patients were observed and evaluated daily during the morning care between 08:00 AM - 8:30 AM for a maximum 7 days. The visual scale contrived by (Fader et al.(2003) which is based on International Contact Dermatit Score, was used for graded the severity of IAD. Scoring is is 0-to 4 and when scoring is increased the severity of the IAD increased. To evaluate skin integrity, the perineal skin of the patients was observed every day by researcher and was recorded to the Perineal Skin Integrity Assesment Form. The number of defecation, stool consistency, and the number of care product (diaper and the novel incontinent care product) was observed daily and was recorded to the Patient Observation Form. The main study outcomes was IAD.We defined IAD having an erithema score of 1 or more, in the skin of buttock, sacrum, thight and groin. |
3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: LEYLA KHORSHID, Professor, Ege University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EGE.0.20.05.00/BOY/1718/99Z
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Incontinence-associated Dermatitis
-
Essity Hygiene and Health ABCompletedIncontinence-associated DermatitisSweden
-
Tan Tock Seng HospitalTerminatedIncontinence-associated DermatitisSingapore
-
University of the PhilippinesCalmoseptine, Inc.CompletedIncontinence Associated DermatitisPhilippines
-
Solventum US LLC3MTerminatedIncontinence-associated DermatitisGermany, United Kingdom, Belgium
-
Solventum US LLC3MTerminatedIncontinence Associated DermatitisUnited States
-
Essity Hygiene and Health ABCompletedIncontinence-associated DermatitisSweden
-
ScotiadermThe Salvation Army Toronto Grace Health CentreNot yet recruitingFecal Incontinence | Incontinence Associated Dermatitis | Moisture Associated Skin Damage
-
ScotiadermNot yet recruitingIntertrigo | Incontinence-associated Dermatitis | Moisture Associated Skin Damage
-
ScotiadermUniversity of Calgary Cumming School of MedicineNot yet recruitingFecal Incontinence | Incontinence Associated Dermatitis | Moisture Associated Skin DamageCanada
-
University Ghent3MCompletedDiaper Rash | Incontinence-associated Dermatitis | Irritant Contact DermatitisBelgium
Clinical Trials on A New Incontinence Care Product
-
Université de SherbrookeActive, not recruitingCardiovascular Diseases | Smoking | Hypertension | Obesity | Diabetes Mellitus, Type 2 | DyslipidemiasCanada
-
University Hospital, ToursCompletedChronic Adult HydrocephalusFrance
-
Chang Gung Memorial HospitalRecruitingQuality of Life | Mobile Apps | OstomyTaiwan
-
Him SACompletedFrail Elderly Syndrome | Congestive Heart Failure | Falls Prevention
-
Him SAUnknownDiabetes | Chronic Obstructive Pulmonary Disease | Frail Elderly Syndrome | Chronic Heart FailureCroatia, Italy, Poland, Spain, United Kingdom
-
Aventure ABCompletedBlood Glucose ResponseSweden
-
Unity Health TorontoRecruitingGestational Diabetes Mellitus in PregnancyCanada
-
Imperial Brands PLCCompleted
-
CochlearWithdrawnHearing LossBelgium, United Kingdom